Product Characteristics and Pharmacological Profile of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in the Phase II Registrational ZUMA-2 Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 50 条
  • [41] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
  • [42] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
  • [43] Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma
    Song, Yuqin
    Li, Jianyong
    Zhou, Keshu
    Ke, Xiaoyan
    Cai, Zhen
    Zhang, Huilai
    Yao, Tingting
    Xia, Zhen
    Wang, Yiqiu
    Lai, Peiqiong
    Liu, Xiaofeng
    Zhu, Jun
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 647 - 652
  • [44] 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Forcade, Edouard
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Zhou, Lang
    Schuberth, Petra C.
    Masouleh, Behzad Kharabi
    Houot, Roch
    ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
  • [45] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    S Ferrero
    A Pastore
    C W Scholz
    R Forstpointner
    A Pezzutto
    L Bergmann
    L Trümper
    J Finke
    U Keller
    P Ghione
    R Passera
    W Hiddemann
    O Weigert
    M Unterhalt
    M Dreyling
    Leukemia, 2016, 30 : 984 - 987
  • [46] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    Ferrero, S.
    Pastore, A.
    Scholz, C. W.
    Forstpointner, R.
    Pezzutto, A.
    Bergmann, L.
    Truemper, L.
    Finke, J.
    Keller, U.
    Ghione, P.
    Passera, R.
    Hiddemann, W.
    Weigert, O.
    Unterhalt, M.
    Dreyling, M.
    LEUKEMIA, 2016, 30 (04) : 984 - 987
  • [47] Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    de Guibert, Sophie
    Zettl, Florian
    Gelbert, Lawrence M.
    Turner, P. Kellie
    Kambhampati, Siva Rama Prasad
    Li, Li
    Li, Lily Q.
    Buchanan, Sean
    Barriga, Susana
    Bear, Melissa M.
    Wilhelm, Martin
    Hess, Georg
    HAEMATOLOGICA, 2021, 106 (03) : 859 - 862
  • [48] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [49] Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
    Gilles Salles
    Jenny M. H. Chen
    Ina Zhang
    Fabio Kerbauy
    James J. Wu
    Sally W. Wade
    Ana Nunes
    Chaoling Feng
    Ioana Kloos
    Weimin Peng
    Julia T. Snider
    Dylan Maciel
    Keith Chan
    Sam Keeping
    Bijal Shah
    Advances in Therapy, 2024, 41 : 1938 - 1952
  • [50] Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
    Salles, Gilles
    Chen, Jenny M. H.
    Zhang, Ina
    Kerbauy, Fabio
    Wu, James J.
    Wade, Sally W.
    Nunes, Ana
    Feng, Chaoling
    Kloos, Ioana
    Peng, Weimin
    Snider, Julia T.
    Maciel, Dylan
    Chan, Keith
    Keeping, Sam
    Shah, Bijal
    ADVANCES IN THERAPY, 2024, 41 (05) : 1938 - 1952
12345